Our Pipeline
This page is intended for investors and commercial partners.
The Mereo BioPharma Pipeline
At Mereo, we draw on deep, trusted relationships across the pharma and biotech ecosystem to carefully select programs that have been deprioritized in other pharmaceutical and biotechnology companies for strategic reasons, but have received significant capital investment, and have the potential to transform the lives of people living with a rare disease.
Through rigorous scientific and commercial insights, flexible and capital-efficient execution, and close collaboration with patient and physician communities as well as healthcare systems, we navigate complex development challenges to create value for all our stakeholders.
The Mereo pipeline is focused on our two lead rare disease programs in osteogenesis imperfecta (OI) and Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD). In addition, we have out-licensed several other clinical stage programs.
Setrusumab (UX-143)
For the potential treatment of osteogenesis imperfecta, a rare genetic bone condition that affects children and adults.
Alvelestat (MPH966)
For the potential treatment of Alpha-1 Antitrypsin Deficiency-associated Lung Disease, a rare genetic condition that results from a deficiency of alpha-1 antitrypsin.
Late-stage pipeline poised to deliver first Phase 3 results
1. per āshibio's website
Pipeline News and Events
Together with patient communities, healthcare professionals, partners and investors, we are constantly making progress in our mission. Keep up to date with the latest stories, developments and milestones.
Mereo BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Highlights
London, November 10, 2025 – Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the third quarter ended September 30, 2025, and provided recent corporate highlights.
Mereo to Participate in Fireside Chat at the Jefferies Healthcare Conference in London
London, November 13, 2025 – Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference in London on Monday, November 17, 2025, at 10:00 am ET / 3:00 pm GMT.
